Actively Recruiting
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Led by City of Hope Medical Center · Updated on 2025-11-05
600
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC). By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-invasive biomarker panel capable of distinguishing responders from non-responders.
CONDITIONS
Official Title
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed metastatic colorectal adenocarcinoma
- Received first-line chemotherapy (FOLFOX or FOLFIRI)
- Availability of pre-treatment serum or plasma samples for cfDNA 5mC/5hmC analysis
- Documented radiologic or clinical response evaluation (RECIST 1.1 or PFS-based)
- RAS/BRAF mutation status available
You will not qualify if you...
- Inadequate cfDNA yield or poor DNA quality
- Non-adenocarcinoma histology
- Active inflammatory or autoimmune disease that may alter cfDNA methylation
- Concomitant malignancy requiring systemic therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
Research Team
A
Ajay Goel, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here